Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Clinical Implications

Clinical Implications

Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.116.08058
Hypertension. 2016;68:521
Originally published August 10, 2016
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Soluble fms-Like Tyrosine Kinase-1 and Heart Failure (p 678)
    • Parental Hypertension and Offspring Arterial Stiffness (p 584)
    • MR in Isoproterenol-Induced Vascular Dysfunction (p 726)
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Soluble fms-Like Tyrosine Kinase-1 and Heart Failure (p 678)

Figure1

Heart failure is a major cause of morbidity and mortality worldwide. Soluble fms-like tyrosine kinase-1 (sFlt-1), an endogenous inhibitor of vascular endothelial growth factor and placental growth factor (PLGF), has been shown to be implicated in the pathogenesis of cardiovascular disease. We have already revealed that production of sFlt-1 is reduced in chronic kidney disease (CKD) and correlates with the development of atherosclerosis and cardiovascular events. Elevated levels of placental growth factor are also associated with a greater risk of cardiovascular events in patients with CKD. However, the significance of sFlt-1 in heart failure remains unclear. Therefore, we investigated the role of sFlt-1 in heart failure, using sFlt-1-knockout mice. In the present study, we demonstrated that decreased sFlt-1 production exacerbates pressure overload–induced infiltration of macrophages into the left ventricle, left ventricular hypertrophy, fibrosis, and subsequent heart failure. Recombinant sFlt-1 protein administration confirmed these findings, and treatment with an anti–placental growth factor-neutralizing antibody (α placental growth factor) or neutralizing monocyte chemoattractant protein-1 antibody inhibited the progression of cardiac hypertrophy and heart failure. Considering the downregulation of sFlt-1 production in CKD, our findings provide a new insight into the molecular mechanism responsible for cardiac remodeling and heart failure accompanied by CKD. Taken together, regulation of endogenous sFlt-1 could be a novel therapeutic target of cardiovascular disease in CKD.

Parental Hypertension and Offspring Arterial Stiffness (p 584)

Figure2

High arterial stiffness is increasingly recognized as a key antecedent of hypertension. Arterial stiffness is moderately heritable, but studies evaluating familial clustering of high arterial stiffness are sparse. Specifically, it is not known whether nonhypertensive offspring of individuals predisposed to develop high blood pressure (by virtue of a positive family history) have higher levels of arterial stiffness relative to their counterparts without parental hypertension. In our community-based sample of young, nonhypertensive adults, we observed greater arterial stiffness indices (carotid-femoral pulse wave velocity, augmentation index, and forward pressure wave amplitude) in those who had parents with hypertension compared with those without parental hypertension. Moreover, offspring who had both parents with hypertension had greater arterial stiffness indices than offspring who had only 1 hypertensive parent. Furthermore, higher arterial stiffness aggregated within families. Additional clinical studies of multiethnic cohorts are warranted to replicate our findings. The clinical corollary of our findings, if confirmed, is that higher aortic stiffness may serve as a valuable clinical biomarker for stratifying the risk of developing high blood pressure in young individuals with a familial predisposition. Potentially, nonhypertensive individuals with parental hypertension who have higher arterial stiffness may be a high-risk group that could be targeted aggressively with nonpharmacological means to prevent future hypertension, a premise that warrants further investigation. The familial aggregation of vascular stiffness suggests that the presence of elevated vascular stiffness in a parent may be an important indicator of higher vascular stiffness in their offspring.

MR in Isoproterenol-Induced Vascular Dysfunction (p 726)

Figure3

Rising circulating catecholamines levels and adrenergic receptor stimulation are common features of many cardiovascular disorders, including hypertension, myocardial infarction, congestive heart failure, and acute cerebrovascular events. Although the hyperadrenergic state has a major and independent prognostic impact in these conditions, the vascular effects of β-adrenoceptor (β-AR) overstimulation are still less understood. In this issue, Victorio et al showed genomic and nongenomic activity of vascular mineralocorticoid receptor (MR) in a model of β-AR overstimulation induced by isoproterenol treatment. The MR blockade with spironolactone prevented the increased vasoconstriction, as well as the reduced nitric oxide levels (Figure) and vascular oxidative stress induced in response to β-AR overstimulation. This beneficial vascular effect of spironolactone was associated with an increased dimerization of the endothelial nitric oxide synthase (Figure) and the chaperone HSP90, suggesting a vasculoprotective signaling induced by MR blockade in hyperadrenergic state. Perivascular adipose tissue has been suggested to be a source of MR ligands including aldosterone and glucocorticoids. The authors reported that β-AR overstimulation can exacerbate glucocorticoid production by perivascular fat without significant changes in circulating levels of this hormone. These results imply that β-AR overstimulation regulates perivascular levels of glucocorticoids and vascular MR activity, revealing an additional mechanism for the benefits of MR blockade in cardiovascular disorders associated with sympathetic overactivation.

  • © 2016 American Heart Association, Inc.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
September 2016, Volume 68, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Soluble fms-Like Tyrosine Kinase-1 and Heart Failure (p 678)
    • Parental Hypertension and Offspring Arterial Stiffness (p 584)
    • MR in Isoproterenol-Induced Vascular Dysfunction (p 726)
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Clinical Implications
    Hypertension. 2016;68:521, originally published August 10, 2016
    https://doi.org/10.1161/HYPERTENSIONAHA.116.08058

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Clinical Implications
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Clinical Implications
    Hypertension. 2016;68:521, originally published August 10, 2016
    https://doi.org/10.1161/HYPERTENSIONAHA.116.08058
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured